DNA vaccine combo shows promise in Hard-to-Treat prostate cancer
NCT ID NCT04090528
First seen Dec 10, 2025 · Last updated May 24, 2026 · Updated 20 times
Summary
This study tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can better control advanced prostate cancer that no longer responds to hormone therapy. About 60 adults with metastatic, castration-resistant prostate cancer will receive either one or two DNA vaccines plus pembrolizumab for up to 2 years. The goal is to see if the two-vaccine combination improves progression-free survival compared to one vaccine alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53705, United States
-
Washington University Siteman Cancer Center
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.